Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
about
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentAn update on larynx cancerImmune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentEmerging therapies for breast cancerEvidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckImmunotherapy in head and neck cancer: aiming at EXTREME precision.Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeLocal Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectivesPrognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapyMethylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervixThe Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literatureMetastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report.Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyTransient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.Immunotherapy for Esophageal Squamous Cell Carcinoma.Clusterization in head and neck squamous carcinomas based on lncRNA expression: molecular and clinical correlates.Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Cancer Immunotherapies: Are They as Effective in the Elderly?The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.Immunotherapy for head and neck cancer: the future of treatment?Cancer Immunotherapy: Whence and Whither.Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.Immunogenomics: using genomics to personalize cancer immunotherapy.Evaluation of dosing strategy for pembrolizumab for oncology indications.Current studies of immunotherapy in head and neck cancer.Safety of drug treatments for head and neck cancer.The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
P2860
Q28076294-AAFE903E-503E-48C1-804B-0404A84DCAA6Q28079132-CDD5399B-5DC1-41AC-9E04-4E2FE636018DQ30235360-4664D52F-D872-46F1-BA98-F1D3252AE5D3Q33607965-8C5C1CC0-B7C0-4DDD-B09D-6BC7C1054C0FQ33617949-06BFDB68-D5D9-423A-AD9E-4D781BBCCAA4Q33650470-3B5E8916-354B-40E9-9E1F-4D8A7357F934Q33756244-C61CA936-BB6F-4284-B15E-D997DBF91DF0Q33757149-9E6517E5-7F38-4695-8881-59811EEA7146Q33788235-E8C20577-6803-4274-80A4-2519C1C14229Q33793552-B1F20BF4-6A2A-4061-8120-592BA212FF08Q33832752-8E45854F-F67F-43C4-BDEA-4124F5F1202FQ33884361-2315CBFC-2406-4BF9-B973-66DEC2455605Q33884484-1E022508-1BB6-4C43-A6BB-4AE3FCEF1D9AQ34541447-6A2D9EF6-7145-4EB8-924B-C1A2976F9AB8Q37516448-DAA91C84-76F4-48A8-98BA-337F0B9ED3F8Q37518341-D66580FB-65D7-49A8-A8C2-9EA833430160Q37584406-0A6C4CB4-6802-4619-A9BD-502C39A33689Q37622998-7B0CD41B-1294-43C4-BBEE-C331BBF6964FQ37629874-28E7625F-E2C8-4E81-B458-22185A417B8AQ37664203-13B235F6-970E-42F1-B2F5-62CF1282B3A4Q37716427-B233BB4B-76DB-43B0-9E93-703530F5F312Q37730966-AF30704F-8355-4C46-90CD-BBABBC888EF2Q37742485-EBEED3F7-7355-4794-BE0B-C373D580FF91Q38635035-49089A9C-B8C5-409D-A9C8-7CC8D1A920B6Q38661479-E137DDDC-C45C-496A-A327-F584CEED346BQ38672084-F6AADF83-C39D-40CF-9FCF-DE00C66CF65BQ38679662-E14CCA88-21C7-4BAF-8026-D801C0B075CBQ38686682-5777EF0E-AA7C-4B8D-9A7B-FC37207F7755Q38687552-F49D6185-C342-43BD-8D67-EA1F95D80D4FQ38709131-6FEC19EB-0BEA-43A6-8C15-9E9B1AD89E45Q38715520-DD387144-2F7D-4175-9923-D6732A84BDC6Q38736238-08AC3C0A-E8B9-437D-9311-231718CADC97Q38737924-1586605D-9A80-48A0-A67B-200C97A7A3B3Q38744053-1D886FE0-845F-481E-9371-830F1A646450Q38772744-74B5EB7A-A39B-4FAB-B2B5-BCF2A614671EQ38779793-50172632-6307-46C7-BA52-A666C52A779BQ38808580-AE9BBAA7-09FA-4E03-A32C-00EAF06FB767Q38809582-58A4F21C-9830-435F-95ED-07E248D86A1AQ38811007-0885BAAF-4856-443A-BAA5-194BE53B936EQ38818008-EA0C855C-8979-404B-B886-6BF4CD851DD6
P2860
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Safety and clinical activity o ...... , multicentre, phase 1b trial.
@en
type
label
Safety and clinical activity o ...... , multicentre, phase 1b trial.
@en
prefLabel
Safety and clinical activity o ...... , multicentre, phase 1b trial.
@en
P2093
P1433
P1476
Safety and clinical activity o ...... , multicentre, phase 1b trial.
@en
P2093
Barbara Burtness
Christine Gause
Jared Lunceford
Jared Weiss
Jonathan D Cheng
Joseph Paul Eder
Karl Heath
Laura Q Chow
Raanan Berger
Ranee Mehra
P304
P356
10.1016/S1470-2045(16)30066-3
P577
2016-05-27T00:00:00Z